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A prospective randomized study was conducted to evaluate the efficacy ofprophylactic intravesical 
instillation of pirarubicin (THP) prior to transurethral resection (TUR) of superficial bladder cancer. 
A total of63 patients were randomized into two groups， the THP group and the control group. In the 
THP group， 30mg of THP dissolved in 50ml saline was administered 4 times intravesically for 4 
consecutive days before TUR. In the control group， no instillation was performed before TUR. The 
patients were followed by cystoscopy and urinary cytology every 3 months. 
The non-recurrence rates in the THP group and control group were 54.1 % versus 37.6% at 1 year 
and 40.4% versus 26.8% at 2 years， respectively (P = 0.086). Time to recurrence for tumors larger 
than 1 cm was significantly longer in the THP group (P=0.0137). Time to recurrence for single and 
grade 1 +2 tumors tended to be longer in the THP group (P=0.09， P=0.079). No significant adverse 
effects were observed in any patient. 
Our findings suggest that intravesical THP instillation prior to TUR would be effective for patients 
with single， low grade lesions larger than 1 cm of superficial bladder cancer 
(Hi町 okikaKiyo 51・439-442，2005)
Key words: S叩 erficial bladder cancer， Pirarubicin (THP)， Intravesical instillation， TUR， 
































腫蕩径 1cm未満，多発， grade 1の症例で341日自に
再発した.逆に増大した症例はなかった.
3 非再発率の検討










































THP注入群は TUR施行前に l日l回， THP 30 
mgを腸脱内に計4回注入した (Fig.1).なお， THP 
の4回目の腸脱内注入は TUR施行当日に実施した.



























Chi-sq .312 24/9 25/5 男/女性別
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3 )腫蕩径別の非再発率 (Fig.3) 
腫蕩径に対する検討の結果， 1 cm以上の腫湯径症
例において THP注入群 (n=16)は対照群 (n=20)
に比べ有意に非再発期間を延長させた (generalized






THP注入群 (n=13)は対照群 (n=1 I)に比べて単発
症例で再発期間の延長傾向が認められた (p=O.09). 
多発の症例では有意な差は認められなかった.
5 )異型度別非再発率 (Fig.5) 
異型度別に対する非再発率の検討では， grade 1と
grade 2の症例で， THP注入群 (n=24)は対照群 (n
=26)に比べて再発抑制期間の延長傾向が認められた
(generalized Wilcoxon test p = O.0788， Logrank test p 






generallzed Wllcoxon 1001 p=0.0900 
Log問nklest p=02141 
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一方， THPの薬剤濃度に関しては， 20 mg/40 ml 
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